Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast Cancer
Status:
Completed
Trial end date:
2012-01-06
Target enrollment:
Participant gender:
Summary
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy, using
exemestane or anastrozole, may fight breast cancer by reducing the production of estrogen. It
is not yet known whether exemestane is more effective than anastrozole in preventing the
recurrence of breast cancer.
PURPOSE: This randomized phase III trial is studying exemestane to see how well it works
compared to anastrozole in preventing cancer recurrence in postmenopausal women who have
undergone surgery for primary breast cancer.
Phase:
Phase 3
Details
Lead Sponsor:
NCIC Clinical Trials Group
Collaborators:
Cancer and Leukemia Group B Eastern Cooperative Oncology Group International Breast Cancer Study Group National Cancer Institute (NCI) North Central Cancer Treatment Group Southwest Oncology Group